Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Why Targeting PSMA is a valuable addition in the management of ...
The role of PSMA in tumorigenesis. PSMA hydrolyses poly-glutamated ...
PSMA and Beyond 2025: Overview of Clinical Trials of PSMA RLT in 2025
Overview of Most Commonly Used Glu-Urea-Based PSMA Ligands | Download Table
Example of a patient with partial remission after addition of ...
APCCC 2024: PSMA Radioligand Therapy – State of the Art
Synthesis and Biological Evaluation of PSMA Ligands with Aromatic ...
PSMA and Beyond 2025: PSMA-I&T vs PSMA-617: Is There a Difference?
Percent change in PSA and prostate/bed, nodal, and osseous disease PSMA ...
177Lu-labeled PSMA targeting therapeutic with optimized linker for ...
AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease
Interrogating heterogeneous PSMA expression in advanced prostate cancer ...
PSMA-avid nonprostate malignancies in three patients. (a) PSMA PET ...
PSMA PET and RLT 2024: PSMA Radioligand Therapy: The VISION and TheraP ...
The real multiplication and real addition of each part of the FA-PSMA ...
PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate ...
Optimization of prostate cancer treatment with PSMA radionuclide ...
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA ...
Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone ...
68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during ...
Addition of 177Lu-PSMA-617 to enzalutamide improves PSA-PFS in mCRPC
ASCO 2023: PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu ...
ESMO 2025: Discussant – Phase III Trial of [177Lu]Lu-PSMA-617 Combined ...
SNMMI 2024: Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive ...
ESMO 2024: Radioligand Theranostics in Prostate Cancer: Status Quo and ...
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of ...
(A) Pluvicto™ accumulates both in PSMA-positive tumors and in ...
SUO 2025: PSMAddition: Top Line Results from a Phase 3 Trial of ADT and ...
Blog - Emsey Hospital
Technology | Prostate Specific Membrane Antigen (PSMA) | Cancer ...
Slide 10
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate ...
PSMAddition: ¹⁷⁷Lu-PSMA-617 Extends PFS in mHSPC
FDA grants breakthrough designation to radioligand therapy for advanced ...
Chemical structures of 177 Lu-PSMA-617 and 177 Lu-PSMA I&T. | Download ...
ASCO 2025: First-in-Human Results of Terbium-161 161Tb-PSMA-I&T ...
PSMA-Expression Is Highly Associated with Histological Subtypes of ...
SUO 2021: VISION Trial: Integrating PSMA-Targeted Therapy for Advanced ...
Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey ...
Pluvicto (177Lu-PSMA-617): What patients need to know? - OncoDaily
ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT ...
ESMO 2021: Health-Related Quality of Life (HRQoL), Pain and Safety ...
PSMA-Addition Trial can give access t... - Advanced Prostate...
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive ...
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with ...
177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with ...
PSMA-Directed Theragnostics: Transforming Prostate Cancer Landscape ...
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single ...
Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A ...
ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach ...
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic ...
First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu ...
Advances In PSMA-Based Approach For Prostate Cancer - Siemens Healthineers
(PDF) Towards Improving the Efficacy of PSMA-Targeting Radionuclide ...
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic ...
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated ...
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with ...
SNMMI 2019: Current Status of 177 Lu-PSMA Targeted Therapies and Where ...
(PDF) Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for ...
Lu177-PSMA Therapy in Germany for Advanced Prostate Cancer | Vaidam Health
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved ...
Schematic representation of PSMA-b-PS reactions with TBP under ...
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant ...
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane ...
[Figure, A pre and post Lu-177-PSMA...] - StatPearls - NCBI Bookshelf
中华医学会核医学分会 新闻中心 四川大学华西医院成功启动放射配体疗法 177Lu-PSMA-617治疗前列腺癌全球多中心随机Ⅲ期临床试验
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model ...
前列腺癌精准疗法！欧盟CHMP建议批准PSMA靶向放射配体疗法Pluvicto_治疗_患者_研究
177Lu-PSMA Therapy | Journal of Nuclear Medicine Technology
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA ...
Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion ...
(PDF) Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a ...
Comparative Preclinical Biodistribution, Dosimetry, and ...
Chemical structure of PSMA-617. 68 Ga and 177 Lu can bind to PSMA-617 ...
Intensified therapy with 177Lu‐PSMA‐I&T in patients with high‐volume ...
177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short ...
PSMA-mediated specific RNP8 binding to cells a, LNCaP (PSMA⁺⁺), 22RV1 ...
EAU 2021: Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic ...
Guideline Recommendation for ADT Treatment in Prostate Cancer | Urology ...
PSMA-Therapie
ASCO 2023: Effects of 177Lu-PSMA-617 on Overall Survival in TheraP ...
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate ...
Pharmaceuticals | Free Full-Text | [177Lu]Lu-PSMA-617 (PluvictoTM): The ...
177Lu-PSMAの作用機序 | keep on going 前立腺がんの知識
Pluvicto前列腺癌靶向治疗新一代核武器 求臻医学探泌臻知 - 哔哩哔哩
